EAM
AGIO icon

Exome Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Exome Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Sell
70,500
-54,560
-44% -$1.66M 1.61% 25
2026
Q1 		$4.23M Sell
125,060
-11,882
-9% -$337K 2.19% 14
2025
Q4 		$3.73M Buy
+136,942
New +$4.8M 1.78% 17
2024
Q4 		– Sell
-66,200
Closed -$2.94M – 62
2024
Q3 		$2.94M Buy
+66,200
New +$3.01M 1.99% 20
2024
Q2 		– Sell
-59,902
Closed -$1.75M – 53
2024
Q1 		$1.75M Buy
+59,902
New +$1.6M 1.5% 29

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Exome Asset Management's AGIO Position: Q2 2026 in Review

Exome Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 44% in Q2 2026, selling an estimated $1.66M and leaving 70,500 shares worth $2.62M. The position accounts for 1.61% of the portfolio, ranked #25.

Exome Asset Management first reported a position in AGIO in Q1 2024 and has held it in 5 quarters since. The position peaked at $4.23M in Q1 2026. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Exome Asset Management held 70,500 shares of Agios Pharmaceuticals worth $2.62M as of Q2 2026.
  • Exome Asset Management sold 54,560 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.66M.
  • Agios Pharmaceuticals made up 1.61% of Exome Asset Management's portfolio in Q2 2026, its #25 holding.
  • Exome Asset Management first reported a position in Agios Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • Exome Asset Management's Agios Pharmaceuticals position peaked at $4.23M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.